Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Placebo-controlled Study of Topical KB105, a Replication-defective, Non-integrating HSV-1 Vector Expressing Human Transglutaminase 1 (TGM1) for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)

Next Previous
Trial Profile

A Phase 2, Randomized, Placebo-controlled Study of Topical KB105, a Replication-defective, Non-integrating HSV-1 Vector Expressing Human Transglutaminase 1 (TGM1) for the Treatment of TGM1-deficient Autosomal Recessive Congenital Ichthyosis (ARCI)

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Inetagugene geperpavec (Primary)
  • Indications Ichthyosis
  • Focus Therapeutic Use
  • Acronyms JADE-1
  • Sponsors Krystal Biotech

Most Recent Events

  • 19 Feb 2025 According to Krystal media release, company is now planning on initiating the Phase 2 portion of its KB105 Phase 1/2 JADE-1 trial for the treatment of TGM1-deficient lamellar ichthyosis in pediatric patients in 2026.
  • 05 Aug 2024 According to Krystal Biotech media release, company expects to commence the Phase 2 portion of JADE-1 trial in pediatric patients in 1H 2025.
  • 07 Aug 2023 According to Krystal Biotech media release, the company plans to initiate phase 2 cohort in this study in 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top